QUINTESSENTIAL-2
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of BMS-986393, a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma
What's the purpose of the trial?
Not yet accepting
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- BMS-986393 (CC-95266)
- Carfilzomib
- Cyclophosphamide
- Daratumumab
- Dexamethasone
- Fludarabine
- Pomalidomide
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Not yet accepting
Not yet accepting
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.